Skip to content
OpenCapital
Get started

Utah Medical Products UTMD Acquired in-process research and development

Acquired in-process research and development at other companies

Avanos Medical logo
Avanos MedicalAVNS
$5.2M-3.7%

Other financials

Income statement

See full
Revenue$8.7M-10.2%
Gross profit$5.3M-4.6%
Operating income$2.6M-18.6%
Net income$2.6M-14.4%
EPS (diluted)$0.82-10.9%

Balance sheet

See full
Cash & equivalents$87.4M+4.9%
Total debt$210.0K—
Total equity$120.4M+2.8%
Total assets$124.4M+1.5%

Cash flow

See full
Operating cash flow$3.1M-30.4%
CapEx$130.0K-29.3%
Free cash flow$3.0M-30.4%

Valuation

See full
Market cap$219.63M+26.4%
Enterprise value$132.44M+42.5%
P/E20.3×+6.4×
P/S5.9×+1.4×

Profitability

See full
Gross margin57.9%-0.4pp
Operating margin28.8%-3.9pp
Net margin28.9%-4.1pp
FCF margin34.7%0.0pp

Returns & leverage

See full
Return on equity9.1%-1.4pp
Debt / equity0×—
Current ratio28.6×+6.3×

Where this comes from

Reported directly by Utah Medical Products in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Utah Medical Products’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Utah Medical Products's acquired in-process research and development.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Utah Medical Products's acquired in-process research and development?
Utah Medical Products (UTMD) reported acquired in-process research and development of $154K in Q1 2026.
How has Utah Medical Products's acquired in-process research and development changed year-over-year?
Utah Medical Products's acquired in-process research and development decreased by 0.0% year-over-year, from $154K to $154K.
What is the long-term trend for Utah Medical Products's acquired in-process research and development?
Over 4 years (2021 to 2025), Utah Medical Products's acquired in-process research and development has grown at a 6.2% compound annual growth rate (CAGR), from $526K to $668K.
What does acquired in-process research and development mean?
Represents the cash outflow for the acquisition of research and development projects that have not yet reached technological feasibility. This metric highlights the company's strategy for inorganic growth and long-term innovation through external technology sourcing.